Record title

Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study

Record identifier

TN_cdi_proquest_miscellaneous_2566254470

https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2566254470

Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study

About this item

Full title

Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study

Publisher

London: Elsevier Ltd

Journal title

The Lancet (British edition), 2021, Vol.398 (10302), p.759-771

Record Identifier

TN_cdi_proquest_miscellaneous_2566254470

Language

English

Formats

Publication information

Publisher

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_2566254470

Permalink

https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2566254470

Other Identifiers

ISSN

E-ISSN

DOI

How to access this item

Online

01
Login with a Library card